Beximco Pharmaceuticals Limited (AIM: BXP)
21.50
0.00 (0.00%)
Sep 11, 2024, 4:14 PM GMT+1
Beximco Pharmaceuticals Income Statement
Financials in millions BDT. Fiscal year is July - June.
Millions BDT. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
---|---|---|---|---|---|---|---|
Period Ending | Mar '24 Mar 31, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | Jun '19 Jun 30, 2019 | 2018 - 2014 |
Revenue | 43,085 | 39,267 | 34,669 | 29,494 | 25,612 | 22,817 | Upgrade
|
Revenue Growth (YoY) | 13.46% | 13.26% | 17.55% | 15.16% | 12.25% | 28.79% | Upgrade
|
Cost of Revenue | 24,457 | 22,151 | 18,989 | 15,677 | 13,787 | 12,259 | Upgrade
|
Gross Profit | 18,628 | 17,116 | 15,681 | 13,816 | 11,825 | 10,557 | Upgrade
|
Selling, General & Admin | 10,873 | 10,214 | 9,101 | 7,470 | 6,451 | 5,689 | Upgrade
|
Operating Expenses | 10,873 | 10,214 | 9,101 | 7,470 | 6,451 | 5,689 | Upgrade
|
Operating Income | 7,755 | 6,902 | 6,580 | 6,346 | 5,374 | 4,868 | Upgrade
|
Interest Expense | -1,137 | -1,242 | -925.6 | -805.87 | -983.2 | -1,013 | Upgrade
|
Interest & Investment Income | 14.74 | 7.46 | 5.07 | 3.32 | 21.84 | 37.95 | Upgrade
|
Earnings From Equity Investments | - | - | - | - | - | -29.33 | Upgrade
|
Currency Exchange Gain (Loss) | -24.15 | 66.94 | 50.12 | -3.72 | 13.2 | -20.01 | Upgrade
|
Other Non Operating Income (Expenses) | 289.9 | 314.3 | 402.75 | 298.91 | 261.72 | 103.82 | Upgrade
|
EBT Excluding Unusual Items | 6,898 | 6,049 | 6,112 | 5,839 | 4,687 | 3,948 | Upgrade
|
Merger & Restructuring Charges | - | - | -57.3 | -18.21 | - | -2.88 | Upgrade
|
Gain (Loss) on Sale of Assets | 18.07 | 13.82 | 12.62 | 3.96 | -33.8 | 1.44 | Upgrade
|
Other Unusual Items | 6.1 | 6.1 | 619.47 | 552.99 | - | - | Upgrade
|
Pretax Income | 6,922 | 6,069 | 6,687 | 6,378 | 4,653 | 3,946 | Upgrade
|
Income Tax Expense | 1,589 | 1,544 | 1,688 | 1,212 | 1,109 | 905.66 | Upgrade
|
Earnings From Continuing Operations | 5,333 | 4,524 | 4,999 | 5,166 | 3,544 | 3,040 | Upgrade
|
Minority Interest in Earnings | -3.01 | 89.6 | 124.51 | -38.06 | -29.8 | -7 | Upgrade
|
Net Income | 5,330 | 4,614 | 5,123 | 5,128 | 3,515 | 3,033 | Upgrade
|
Net Income to Common | 5,330 | 4,614 | 5,123 | 5,128 | 3,515 | 3,033 | Upgrade
|
Net Income Growth | 19.05% | -9.94% | -0.09% | 45.89% | 15.87% | 19.59% | Upgrade
|
Shares Outstanding (Basic) | 446 | 446 | 446 | 446 | 446 | 446 | Upgrade
|
Shares Outstanding (Diluted) | 446 | 446 | 446 | 446 | 446 | 446 | Upgrade
|
Shares Change (YoY) | - | - | - | - | -0.00% | - | Upgrade
|
EPS (Basic) | 11.95 | 10.34 | 11.48 | 11.49 | 7.88 | 6.80 | Upgrade
|
EPS (Diluted) | 11.95 | 10.34 | 11.48 | 11.49 | 7.88 | 6.80 | Upgrade
|
EPS Growth | 19.05% | -9.94% | -0.09% | 45.89% | 15.87% | 19.59% | Upgrade
|
Free Cash Flow | 6,337 | 3,674 | 2,399 | 3,503 | 3,299 | -1,457 | Upgrade
|
Free Cash Flow Per Share | 14.21 | 8.24 | 5.38 | 7.85 | 7.39 | -3.26 | Upgrade
|
Dividend Per Share | 3.500 | 3.500 | 3.500 | 3.500 | 1.364 | 1.364 | Upgrade
|
Dividend Growth | 0% | 0% | 0% | 156.67% | 0% | 19.99% | Upgrade
|
Gross Margin | 43.24% | 43.59% | 45.23% | 46.85% | 46.17% | 46.27% | Upgrade
|
Operating Margin | 18.00% | 17.58% | 18.98% | 21.52% | 20.98% | 21.34% | Upgrade
|
Profit Margin | 12.37% | 11.75% | 14.78% | 17.39% | 13.72% | 13.29% | Upgrade
|
Free Cash Flow Margin | 14.71% | 9.36% | 6.92% | 11.88% | 12.88% | -6.38% | Upgrade
|
EBITDA | 9,438 | 8,636 | 8,247 | 7,460 | 6,488 | 5,811 | Upgrade
|
EBITDA Margin | 21.91% | 21.99% | 23.79% | 25.29% | 25.33% | 25.47% | Upgrade
|
D&A For EBITDA | 1,683 | 1,734 | 1,667 | 1,114 | 1,114 | 942.76 | Upgrade
|
EBIT | 7,755 | 6,902 | 6,580 | 6,346 | 5,374 | 4,868 | Upgrade
|
EBIT Margin | 18.00% | 17.58% | 18.98% | 21.52% | 20.98% | 21.34% | Upgrade
|
Effective Tax Rate | 22.95% | 25.45% | 25.25% | 19.00% | 23.83% | 22.95% | Upgrade
|
Advertising Expenses | - | 212.23 | 196.72 | 160 | 140.88 | 82.3 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.